Kim A. Margolin, MD, of City of Hope, summarizes a session she co-chaired on combination immunotherapies, locoregional therapies, systemic therapies, and enhancing natural killer cells.
Nicolas Guibert, MD, PhD, of Toulouse University Hospital, discusses a simple algorithm built to predict durable outcomes of patients with advanced non–small cell lung cancer...
Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the data to date on checkpoint blockades and the rationale for combination therapies and novel ...
G. Travis Clifton, MD, of Brooke Army Medical Center, discusses phase IIb trial findings on nelipepimut-S plus GM-CSF with trastuzumab vs trastuzumab alone to prevent recurre...
Toni K. Choueiri, MD, and Ziad Bakouny, MD, both of Dana-Farber Cancer Institute, talk about novel cytokines, checkpoint inhibitors, and vaccines in the trea...
Stefan O. Ciurea, MD, of The University of Texas MD Anderson Cancer Center, discusses the enhanced antitumor effect and lower viral reactivation that result from high doses of natu...
